No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
PLX Protalix Biotherapeutics
- 1.760
- +0.020+1.15%
Close Dec 20 16:00 ET
- 1.760
- 0.0000.00%
Post 18:22 ET
129.60MMarket Cap-11.73P/E (TTM)
1.785High1.690Low344.36KVolume1.690Open1.740Pre Close601.48KTurnover0.63%Turnover Ratio19.56P/E (Static)73.63MShares1.90052wk High3.99P/B96.36MFloat Cap0.82152wk Low--Dividend TTM54.75MShs Float1037.500Historical High--Div YieldTTM5.46%Amplitude0.700Historical Low1.746Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for Pegunigalsidase Alfa
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript Summary
Protalix BioTherapeutics Reports Profit In Q3; Announces Positive Phase 1 Data For PRX-115
Protalix Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Protalix Biotherapeutics | 8-K: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $18M
Heat List
US
Overall
Symbol
Price
% Chg
No Data